Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.4K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Coagulation01:09

Coagulation

8.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

60
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
60
Introduction to Hemostasis01:05

Introduction to Hemostasis

9.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
9.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States.

Blood advances·2026
Same author

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Heterogeneity Among Plasma-Derived von Willebrand Factor Concentrates: Implications for Comparative Effectiveness Analyses.

Seminars in thrombosis and hemostasis·2026
Same author

Bleeding Phenotypes in Inherited Platelet Function Disorders: Insights From the ATHNdataset.

Journal of pediatric hematology/oncology·2026
Same author

Seventh Åland Island Meeting on von Willebrand Disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Menstrual Health & Heavy Menstrual Bleeding in Congenital Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Related Experiment Video

Updated: Oct 18, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.7K

Hemophilia B (Factor IX Deficiency).

Robert F Sidonio1, Lynn Malec2

  • 1Emory University, 1760 Haygood Drive, HSRB W340, Atlanta, GA 30322, USA.

Hematology/Oncology Clinics of North America
|October 5, 2021
PubMed
Summary

Hemophilia B, caused by factor IX deficiency, differs biologically from hemophilia A. Understanding factor IX distribution and new treatments like extended half-life products is key for managing hemophilia B.

Keywords:
Extravascular distributionFactor IXHemophilia BProphylaxisTreatment

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.4K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K

Related Experiment Videos

Last Updated: Oct 18, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.7K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.4K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K

Area of Science:

  • Hematology
  • Hemostasis
  • Factor IX Biology

Background:

  • Hemophilia B results from factor IX deficiency, distinct from hemophilia A (factor VIII deficiency).
  • Factor IX plays a unique role in the coagulation cascade and hemostasis.
  • Understanding these biological differences is crucial for effective treatment.

Purpose of the Study:

  • To explore the unique biology of factor IX in hemostasis.
  • To discuss the implications of factor IX distribution on dosing strategies for factor concentrates.
  • To review current and innovative treatments for hemophilia B prophylaxis.

Main Methods:

  • Literature review of factor IX biology and hemophilia B treatments.
  • Analysis of factor IX distribution in extravascular spaces.
  • Examination of extended half-life products and emerging therapies.

Main Results:

  • Factor IX distribution into extravascular space influences its in vivo activity and half-life.
  • Extended half-life factor IX products improve pharmacokinetic profiles, allowing for less frequent dosing.
  • Ongoing research focuses on gene therapy and novel factor IX-bypassing agents.

Conclusions:

  • The unique biology of factor IX necessitates specific treatment approaches for hemophilia B.
  • Optimized dosing strategies and advanced therapies are improving prophylaxis and patient outcomes.
  • Continued innovation in hemophilia B treatment holds promise for enhanced patient care.